Taysha Gene Therapies Inc (TSHA)
🔔 Watch stock
symbol.quality_heading
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
It is not solvency that is the problem — the cash lasts into 2028, a going-concern qualification is deliberately absent. The risk is the single-drug bet: if the FDA says yes to TSHA-102, the value can multiply; if it says no or demands a further trial, the only pillar falls, and the full cash box merely lengthens the road down. On top comes ongoing dilution. Whoever gets in should have understood this binary bet — not follow the red label and not the price jump. The decision is yours.
symbol.quality_note
Taysha builds a "living medicine" from a virus that is meant to stop one of the cruelest childhood diseases — Rett syndrome. The stock turns up in our insolvency warning scanner, and at first that fits: not a cent of revenue, $753.7 million in accumulated deficit, a loss that keeps growing. But whoever reads the annual report (10-K) for 2025 and the quarterly report (10-Q) as of March 31, 2026 pauses: $276.6 million in cash, runway per the company into 2028, no going-concern qualification from the auditor. The warning label is a smoke detector, not a fire — the real bet lies elsewhere. Not investment advice — just a cash count behind the red warning sign.
Read the analysis
Stock Watch
This analysis is as of July 15, 2026. Stock Watch will tell you what's changed at TSHA since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 13 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 5.90 $ — 75% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralTaysha ist ein klinisches Gentherapie-Unternehmen; sein Wert hängt am Wirkstoff TSHA-102 (AAV9) gegen das Rett-Syndrom, nicht an KI. In den ausgewerteten Filings taucht KI ausschließlich als Randthema auf — als internes Arbeitswerkzeug der Mitarbeiter und als allgemeines Compliance-/Datenschutz-Risiko. KI ist weder Umsatzquelle noch ein konkret auf das eigene Geschäftsmodell bezogenes Wettbewerbsrisiko. Damit greift keine der Kategorien „verkauft“, „nutzt“ oder „bedroht“; es bleibt ein dokumentierter Neutral-Befund.
View the full file — quotes, sources, reviewed filings
„Our employees and personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Beschäftigten und Mitarbeiter nutzen generative Technologien der künstlichen Intelligenz (KI) für ihre Arbeit, und die Offenlegung und Nutzung personenbezogener Daten in KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und sonstigen Datenschutzpflichten.
„Governments have passed and are likely to pass additional laws and regulations regulating AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits."
Regierungen haben zusätzliche Gesetze und Vorschriften zur Regulierung von KI erlassen und werden dies wahrscheinlich weiter tun. Unsere Nutzung dieser Technologie könnte zusätzliche Compliance-Kosten, aufsichtsbehördliche Untersuchungen und Verfahren sowie Klagen nach sich ziehen.
Filings Reviewed: 10-K 2026-03-19 · 10-K 2025-02-26 · 10-Q 2026-05-06 · 10-Q 2025-11-04 · 10-Q 2025-08-12 · 10-Q 2025-05-15
Rated on July 14, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 120.3% above the current price.
- Consensus
- Strong Buy
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.11 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.09 | -135.90 | 2 | -43.90 | -929.00 | -18 | -18 |
| 2025: Q1 | -0.08 | – | 2 | -32.50 | -935.20 | -22 | -22 |
| 2025: Q2 | -0.09 | – | 2 | 78.60 | -1,353.60 | -20 | -20 |
| 2025: Q3 | -0.09 | – | 0 | -100.00 | – | -24 | -24 |
| 2025: Q4 | -0.09 | – | 6 | 171.30 | -507.80 | -27 | -27 |
| 2026: Q1 | -0.12 | – | 0 | -100.00 | – | -41 | -44 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Assessment: Opportunities & Risks
Surprisingly solid for a clinical biotech: $276.6 million in cash (March 31, 2026), runway per the report "into 2028", and in 2025 the cash balance even rose by $180.9 million. Unlike comparable warning-scanner hits, there is NO going-concern qualification from the auditor.
TSHA-102 carries strong FDA designations (Breakthrough Therapy, RMAT, Fast Track, Orphan Drug) and showed an early response rate of 83 percent (5 of 6 patients, high dose, May 2025 data cut). The design of the pivotal REVEAL trial is aligned with the FDA. But the trial is small and single-arm — the outcome remains open.
TSHA-102 is, per the company's own report, the "sole product candidate in clinical development". The entire company value hangs on one molecule and a single FDA decision — without a second pillar as a safety net. A no, or the demand for a further trial (as in the Replimune case), would let the only load-bearing pillar give way.
Without revenue, Taysha finances itself almost entirely through new shares: $274.6 million fresh in 2025 alone (of which $264.0 million through shares), about 287 million shares plus pre-funded warrants. The capital need does not end with the cash lasting into 2028 — an approval process and building commercial operations are likely to cost further shares.
The warning scanner "Going Concern (Distress-Proxy)" flags Taysha for real (Altman Z near zero, Piotroski 4 of 9, rating D) — but the metric is structurally strict for a revenue-less lab. At the same time a strong price rally is under way (plus 178.7 percent over twelve months, data as of July 13, 2026) and about 96 percent of the shares are held by institutions: the market takes the bet seriously but has not decided it.
Taysha is the opposite of what the red warning sign suggests: more solid financially than the insolvency scanner implies ($276.6 million in cash, runway into 2028, no going-concern qualification) — and nonetheless one of the riskiest bets on the market. Because the entire value hangs on a single drug, TSHA-102 against Rett syndrome, and on a single FDA decision. No revenue, a growing loss, constant dilution — set against strong medical designations and encouraging early data. A binary event. Not investment advice.
- Taysha reports on a calendar-year basis (fiscal year ends December 31). Program and trial updates appear partly mid-year via press release — when in doubt, reconcile against the filing periods.
- The financing chart sums the three 2025 capital sources per the 10-K (May 2025 placement $215.6 million, Trinity loan $50.0 million Tranche A, ATM sale $48.4 million); the reported net financing inflow for 2025 was $274.6 million.
- Price and scanner figures are dated July 13, 2026 (plus 178.7 percent over twelve months; about 287 million shares); analyses are evergreen, daily prices are not a buy argument.
About the Company
Taysha Gene Therapies, Inc., ein Biotechnologieunternehmen im klinischen Stadium, konzentriert sich auf Entwicklung und Vermarktung von AAV-basierten Gentherapien zur Behandlung schwerer monogener Erkrankungen des zentralen Nervensystems.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 99 |
| Headquarters | Dallas, TX |
| Website | tayshagtx.com |
| IPO Date | 24. Sep 2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Sean P. Nolan | CEO & Chairman | 1968 |
| Sukumar Nagendran M.D. | President, Head of Research & Development and Director | 1967 |
| Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary | 1978 |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | – |
| Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer | – |
| Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer | – |
| Sean McAuliffe | Chief Business Officer | – |
| Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | – |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program | – |
| Rumana Haque-Ahmed | Chief Regulatory Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.